Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)-Reference-Cited by-同舟云学术

Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)

Published:2021-12 Issue:12 Volume:21 Page:e985-e999
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Abrisqueta Pau,Loscertales Javier,Terol Maria José,Ramírez Payer Ángel,Ortiz Macarena,Pérez Inmaculada,Cuellar-García Carolina,Fernández de la Mata Margarita,Rodríguez Alicia,Lario Ana,Delgado Julio,Godoy Ana,Arguiñano Pérez José Mª,Berruezo Mª José,Oliveira Ana,Hernández-Rivas José-Ángel,García Malo Maria Dolores,Medina Ángeles,García Martin Paloma,Osorio Santiago,Baltasar Patricia,Fernández-Zarzoso Miguel,Marco Fernando,Vidal Manceñido Mª Jesús,Smucler Simonovich Alicia,López Rubio Montserrat,Jarque Isidro,Suarez Alexia,Fernández Álvarez Rubén,Lancharro Anchel Aima,Ríos Eduardo,Losada Castillo María del Carmen,Pérez Persona Ernesto,García Muñoz Ricardo,Ramos Rafael,Yáñez Lucrecia,Bello José Luis,Loriente Cristina,Acha Daniel,Villanueva Miguel

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference51 articles.

1. Perturbation of the normal immune system in patients with CLL;Forconi;Blood,2015

2. The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment;Gaidano;Hematology Am Soc Hematol Educ Program,2017

3. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia;Nadeu;Leukemia,2018

4. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial;Eichhorst;Lancet Oncol,2016

5. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German chronic lymphocytic leukemia study group;Fischer;J Clin Oncol,2011

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The new life of ibrutinib therapy in CLL: enhancing personalized approaches;Expert Review of Anticancer Therapy;2024-07-15

2. A retrospective observational study of ibrutinib in chronic lymphocytic leukaemia in a real-life setting in France using the national claims database (OSIRIS);Annals of Hematology;2024-07-05

3. Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines;Blood Reviews;2024-05

4. Real-World Outcome of Treatment with Single-Agent Ibrutinib in Italian Patients with Chronic Lymphocytic Leukemia: Final Results of the EVIdeNCE Study;Cancers;2024-03-20

5. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia;PharmacoEconomics;2024-01-06